Diversion Control Division, US Department of Justice, Drug Enforcement Administration

RESOURCES > Federal Register Notices > Rules - 2013 > Order With Opportunity for Comment: Exempt Chemical Preparations Under the Controlled Substances Act

Rules - 2013

[Federal Register Volume 78, Number 128 (Wednesday, July 3, 2013)]
[Notices]
[Pages 40175-40186]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-16010]


DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-372]

Exempt Chemical Preparations Under the Controlled Substances Act

AGENCY: Drug Enforcement Administration (DEA), Department of Justice.

ACTION: Order with opportunity for comment.


SUMMARY: The applications for exempt chemical preparations received by DEA between July 1, 2012, and March 31, 2013, as listed below, were accepted for filing and have been approved or denied as indicated.

DATES: Electronic comments must be submitted and written comments must be postmarked on or before September 3, 2013. The electronic Federal Docket Management System will not accept comments after midnight Eastern Time on the last day of the comment period.

ADDRESSES: To ensure proper handling of comments, please reference "Docket No. DEA-372" on all electronic and written correspondence. DEA encourages that all comments be submitted electronically through http://www.regulations.gov using the electronic comment form provided on that site. An electronic copy of this document is also available at http://www.regulations.gov for easy reference. Paper comments that duplicate the electronic submission are not necessary as all comments submitted to www.regulations.gov will be posted for public review and are part of the official docket record. Written comments submitted via regular or express mail should be sent to the Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODL, 8701 Morrissette Drive, Springfield, Virginia 22152.

[[Page 40176]]

FOR FURTHER INFORMATION CONTACT: John W. Partridge, Executive Assistant, Office of Diversion Control, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, Virginia 22152; Telephone: (202) 307-7165.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

Please note that all comments received are considered part of the public record and made available for public inspection online at http://www.regulations.gov and in the DEA's public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "PERSONAL IDENTIFYING INFORMATION" in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "CONFIDENTIAL BUSINESS INFORMATION" in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be posted online or made available in the public docket.

Personal identifying information and confidential business information identified and located as set forth above will be redacted, and the comment, in redacted form, will be posted online and placed in DEA's public docket file. Please note that the Freedom of Information Act applies to all comments received. If you wish to inspect the agency's public docket file in person by appointment, please see the FOR FURTHER INFORMATION CONTACT paragraph.

Legal Authority

DEA implements and enforces Titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, often referred to as the Controlled Substances Act and the Controlled Substances Import and Export Act (codified at Title 21, Chapter 13 of the U.S.C.), as amended (CSA). DEA drafts and publishes the implementing regulations for these statutes in Title 21 of the Code of Federal Regulations (CFR), parts 1300 to 1321. The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while providing for a sufficient supply of controlled substances and listed chemicals for legitimate medical, scientific, research, and industrial purposes. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety.

Section 201 of the CSA (21 U.S.C. 811) authorizes the Attorney General, by regulation, to exempt from certain provisions of the CSA certain compounds, mixtures, or preparations containing a controlled substance, if he finds that such compounds, mixtures, or preparations meet the requirements detailed in 21 U.S.C. 811(g)(3)(B).\1\ DEA regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria by which the DEA Deputy Assistant Administrator may exempt a chemical preparation or mixture from the application of certain provisions of the CSA. The Deputy Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which exemptions are granted and modify the scope of exemptions at any time.

---------------------------------------------------------------------------

\1\ This authority has been delegated from the Attorney General to the Administrator of the DEA by 28 CFR 0.100 and subsequently redelegated to the Deputy Assistant Administrator pursuant to the Appendix to Subpart R of 28 CFR 0.104.

---------------------------------------------------------------------------

Exempt Chemical Preparation Applications Submitted Between July 1, 2012, and March 31, 2013

The Deputy Assistant Administrator received applications between July 1, 2012, and March 31, 2013, requesting exempt chemical preparation status pursuant to 21 CFR 1308.23. Pursuant to the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Deputy Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart I below is intended for laboratory, industrial, educational, or special research purposes and not for general administration to a human being or other animal and either: (1) Contains no narcotic controlled substance and is packaged in such a form or concentration that the packaged quantity does not present any significant potential for abuse; or (2) contains either a narcotic or non-narcotic controlled substance and one or more adulterating or denaturing agents in such a manner, combination, quantity, proportion, or concentration that the preparation or mixture does not present any potential for abuse; if the preparation or mixture contains a narcotic controlled substance, it must be formulated in such a manner that it incorporates methods of denaturing or other means so that the preparation or mixture is not liable to be abused or have ill effects if abused, and so that the narcotic substance cannot in practice be removed.

Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23, and 21 CFR 1308.24, the Deputy Assistant Administrator has determined that each of the chemical preparations or mixtures generally described in Chart I below and specifically described in the application materials received by DEA, are exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822-823, 825-829, and 952-954) of the CSA, and 21 CFR 1301.74, as of the date listed below that was provided in the approval letters to the individual requesters.

Chart I
Supplier Product name Form Application
date
AccuStandard, Inc APP–9–086, a,a-Dimethylphenethylamine Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc APP–9–086–20X, a,a-Dimethylphenethylamine Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc AS–E1179, Chloral hydrate Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc CLP–HC–X1, Composite Mix #3A Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc M–551.1B, Disinfectant by-products Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc M–551B, Disinfectant by-products Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc M–551B–2, Chloral hydrate Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc M–8015B/5031–21, Paraldehyde Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc M–8206B–05, Additional VOC's by Method 8206B Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc M–8270–02, Semi-Volatile by Capillary Column GC/MS Mix 2 Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc M–8270–04–ASL, Method 8270B—Base/Neutrals Mix Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc M–8270–23–R1, Method 8270 Semi-Volatile Additions Amber ampule: 1 mL 1/28/2013
AccuStandard, Inc M–E–1179–M, Chloral hydrate Amber ampule: 1 mL 1/28/2013
Agilent Technologies Veterinary Drugs Checkout Mix Amber ampule: 1 mL 8/3/2012
Agilent Technologies Veterinary Drugs Comprehensive Mix—Submix 6 Amber ampule: 1 mL 8/3/2012
Agilent Technologies Forensic Toxicology Comprehensive Mix—Submix 3 Amber ampule: 1 mL 8/3/2012
Agilent Technologies Forensic Toxicology Comprehensive Mix—Submix 5 Amber ampule: 1 mL 8/3/2012
Agilent Technologies Forensic Toxicology Comprehensive Mix—Submix 2 Amber ampule: 1 mL 8/3/2012
Agilent Technologies Forensic Toxicology Checkout Mix Amber ampule: 1 mL 8/3/2012
Agilent Technologies Forensic Toxicology Comprehensive Mix—Submix 1 Amber ampule: 1 mL 12/6/2012
Alltech Associates, Inc 2C–T–2 Quik Check, 1.0 mg/mL Glass ampule: 1 mL 9/26/2012
Alltech Associates, Inc 5-MeO–DMT Quick Check, 1.0 mg/mL Glass ampule: 1 mL 9/26/2012
Alltech Associates, Inc Carisoprodol Quik Check, 1.0 mg/mL Glass ampule: 1 mL 9/26/2012
American Proficiency Institute American Proficiency Institute SHBG/Testosterone Amber bottle: 7 mL 12/5/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Oral Fluid, OF23 Glass vials: 1 ml–200 mL 8/14/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, SD17 Glass vials: 1 ml–200 mL 8/14/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC176 Glass vials: 1 ml–200 mL 9/27/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC179 Glass vials: 1 ml–200 mL 10/23/2012
Biochemical Diagnostics, Inc Salivabuse Custom Liquid Control Oral Fluid, OF25 Glass vials: 1 ml–200 mL 10/23/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC177 Glass vials: 1 ml–200 mL 11/5/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC178 Glass vials: 1 ml–200 mL 1/24/2013
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Oral Fluid, OF24 Glass vials: 1 ml–200 mL 1/24/2013
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC181 Glass vials: 1 ml–200 mL 1/29/2013
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC183 Glass vials: 1 ml–200 mL 3/12/2013
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC184 Glass vials: 1 ml–200 mL 3/12/2013
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC180 Glass vials: 1 ml–200 mL 3/14/2013
Bio-Rad Laboratories Liquichek Immunoassay Plus Control Trilevel MiniPak Box: 3 vials, 2.5 mL each 11/14/2012
Bio-Rad Laboratories Liquichek Immunoassay Plus Control Level 1,2 and 3, Trilevel Box: 12 vials, 5 mL each 11/21/2012
Bio-Rad Laboratories Liquid Assayed Multiqual Premium, Levels 1–3 Box: 6 vials, 5 mL each 11/21/2012
Bio-Rad Laboratories Liquid Assayed Multiqual Premium, Trilevel Minipak Box: 3 vials, 5 mL each 11/21/2012
Bio-Rad Laboratories Lyphocheck Urine Toxicology Control MiniPak, Cat. No. 470X Glass vial: 25 mL 1/11/2013
Bio-Rad Laboratories Liquichek Immunoassay Plus Control Level 1 Glass vial: 2.5 mL, Box 12 vials 2/20/2013
Bio-Rad Laboratories Liquichek Immunoassay Plus Control Level 2 Glass vial: 2.5 mL, Box 12 vials 2/20/2013
Bio-Rad Laboratories Liquichek Immunoassay Plus Control Level 3 Glass vial: 2.5 mL, Box 12 vials 2/20/2013
Cerilliant Corporation Benzodiazepine Mix (1 mg/mL) Glass Ampule: 1 mL 7/2/2012
Cerilliant Corporation Class C Mix Urinalysis Internal Standard Fortified Morphine Glass Ampule: 1 mL 7/9/2012
Cerilliant Corporation Spice Cannabinoid Mix 2 (0.1 mg/mL) Amber ampule: 1 mL 9/26/2012
Cerilliant Corporation Spice Cannabinoid Mix 3 (0.1 mg/mL) Amber ampule: 1 mL 9/26/2012
Cerilliant Corporation Retigabine (1 mg/mL) Glass Ampule: 1 mL 11/7/2012
Cerilliant Corporation ±-Norpseudoephedrine-D3 HCl (0.1 mg/mL) Glass Ampule: 1 mL 1/7/2013
Cerilliant Corporation Amobarbital-D5 (0.1 mg/mL) Glass Ampule: 1 mL 1/7/2013
Cerilliant Corporation 2,5-Dimethoxy-4-(n)-propylthiophenethylamine HCl (2C–T–7 HCl) (1 mg/mL) Glass Ampule: 1 mL 1/7/2013
Cerilliant Corporation Class B Mix Urinalysis Internal Standard-8 (0.002–0.2 mg/mL), Pregabalin-D6 (1.0 mg/mL), Codeine-6-betaglucoronide (1.0 mg/mL), Desomorphine (1.0 mg/mL), Levorphanol-D3 (0.1 mg/mL) Glass Ampule: 1 mL 1/22/2013
Cerilliant Corporation Zaleplon-D4 (0.1 mg/mL) Glass Ampule: 1 mL 1/31/2013
Cerilliant Corporation Retigabine-D4 (0.1 mg/mL) Glass Ampule: 1 mL 3/22/2013
Cerilliant Corporation Tilidine-D6 HCl (0.1 mg/mL) Glass Ampule: 1 mL 3/22/2013
Cliniqa Corporation TDM Control, Levels 1–3 Dropper bottle: 5 mL 12/4/2012
ElSohly Laboratories, Inc ELI Oral Fluid Controls, THC (0.5–50 ng/mL) Glass vial: 5 ml–4 L 10/22/2012
ElSohly Laboratories, Inc ELI Oral Fluid Controls, Methamphetamine (2–200 ng/mL) Glass vial: 5 ml–4 L 10/22/2012
ElSohly Laboratories, Inc ELI Oral Fluid Controls, Amphetamine, Benzoylecgonine, Morphine, Phencyclidine (2–200 ng/mL) Glass vial: 5 ml–4 L 10/22/2012
ElSohly Laboratories, Inc ELI Oral Fluid Controls, Multidrug (THC, Benzoylecgonine, Amphetamine, Methamphetamine, Morphine, Codeine, 6-Acetylmorphine, & PCP) at 0.5–50 ng/mL Glass vial: 5 ml–4 L 10/22/2012
ElSohly Laboratories, Inc ELI Oral Fluid Calibrators, THC (0.5–50 ng/mL) Glass vial: 5 ml–4 L 10/22/2012
ElSohly Laboratories, Inc ELI Oral Fluid Calibrators, Methamphetamine (2–200 ng/mL) Glass vial: 5 ml–4 L 10/22/2012
ElSohly Laboratories, Inc ELI Oral Fluid Calibrators, Amphetamine, Benzoylecgonine, Morphine, Phencyclidine (2–200 ng/mL) Glass vial: 5 ml–4 L 10/22/2012
ElSohly Laboratories, Inc ELI Oral Fluid Calibrators, Multidrug (THC, Benzoylecgonine, Amphetamine, Methamphetamine, Morphine, Codeine, 6-Acetylmorphine, & PCP) at 0.5–200 ng/mL Glass vial: 5 ml–4 L 10/22/2012
Environmental Resource Associates (ERA) USGS–BQS LS 4434 Mix 1 Glass Ampule: 2 mL 8/9/2012
Environmental Resource Associates (ERA) USGS–BQS LS 4434 Mix 2 Glass Ampule: 2 mL 8/9/2012
Immunalysis Corporation Tapentadol Calibrator Level 1 (100 ng/mL) Glass vial: 10 mL 12/11/2012
Immunalysis Corporation Tapentadol Calibrator Level 2 (200 ng/mL) Glass vial: 10 mL 12/11/2012
Immunalysis Corporation Tapentadol Calibrator Level 3 (500 ng/mL) Glass vial: 10 mL 12/11/2012
Immunalysis Corporation Tapentadol Calibrator Level 4 (1,000 ng/mL) Glass vial: 10 mL 12/11/2012
Immunalysis Corporation Tapentadol Low Control (150 ng/mL) Glass vial: 10 mL 12/11/2012
Immunalysis Corporation Tapentadol High Control (250 ng/mL) Glass vial: 10 mL 12/11/2012
LGC Limited (S)-(+)-Amphetamine (Dextroamphetamine) 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Amphetamine 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Amphetamine 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Amphetamine-D11 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Amphetamine-D11 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Amphetamine-D5 (D-label on ring) 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Methamphetamine ((S)-(+)-Methamphetamine) 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Methamphetamine 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Methamphetamine 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Methamphetamine-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Methamphetamine-D5 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Methcathinone Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 9/24/2012
LGC Limited Methylphenidate Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 9/24/2012
LGC Limited Amobarbital 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Pentobarbital 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Pentobarbital-D5 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Pentobarbital-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Secobarbital 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-MDA–D5 (rac-3,4-Methylenedioxyamphetamine-D5) 0.1 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-MDA–D5 (rac-3,4-Methylenedioxyamphetamine-D5) 1.0 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-MBDB HCl (rac-N-Methyl-1-(3,4-Methylenedioxyphenyl)-2-butanamine Hydrochloride) 1.0 mg/mL Methanol (as free base) Glass vial: 1 mL 9/24/2012
LGC Limited rac-MBDB–D5 (rac-N-Methyl-1-(3,4-Methylenedioxyphenyl)-2-butanamine-D5) 0.1 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-MDEA–D5 (rac-3,4-Methylenedioxy-N-ethylamphetamine-D5) 0.1 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-MDEA–D5 (rac-3,4-Methylenedioxy-N-ethylamphetamine-D5) 1.0 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-MDEA–D6 (rac-3,4-Methylenedioxy-N-ethylamphetamine-D6) 0.1 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-MDMA–D5 (rac-3,4-Methylenedioxymethamphetamine-D5) 0.1 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-MDMA–D5 (rac-3,4-Methylenedioxymethamphetamine-D5) 1.0 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Phencyclidine (PCP) 1.0 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Phencyclidine-D5 (PCP-D5) 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Phencyclidine-D5 (PCP-D5) 1.0 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Codeine 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Codeine 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Codeine-D3 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Codeine-D3 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Codeine-D6 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Codeine-D6 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Isocodeine 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Norcodeine 0.01 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Norcodeine 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Codeine N-Oxide 0.01 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Oxycodone-D3 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Oxycodone-D6 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Oxycodone-D6 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Hydromorphone 1.0 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Norhydromorphone Hydrochloride 1.0 mg/mL Methanol (as free base) Glass vial: 1 mL 9/24/2012
LGC Limited Pethidine (Meperidine) 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Pethidine-D4 (Meperidine-D4) 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Pethidine-D4 (Meperidine-D4) 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Morphine 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Morphine 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Morphine 3-beta-D-Glucuronide 0.1 mg/mL in Methanol/Water (1⁄1) Glass vial: 1 mL 9/24/2012
LGC Limited Morphine 3-beta-D-Glucuronide 1.0 mg/mL in Methanol with 0.05 percent Sodium Hydroxide (w/v) Glass vial: 1 mL 9/24/2012
LGC Limited Morphine 6-beta-D-Glucuronide 0.1 mg/mL in Methanol/Water (1⁄1) Glass vial: 1 mL 9/24/2012
LGC Limited Morphine 6-beta-D-Glucuronide 1.0 mg/mL Water/Methanol (80/20) Glass vial: 1 mL 9/24/2012
LGC Limited Morphine-D3 0.1 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Morphine-D3 1.0 mg/mL in Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Morphine N-Oxide 0.01 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited Normorphine 1.0 mg/mL Methanol Glass vial: 1 mL 9/24/2012
LGC Limited rac-Amphetamine-D10 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Amphetamine-D5 (D-label on ring) 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Amphetamine-D5 (D-label on side chain) 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Amphetamine-D5 (D-label on side chain) 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Amphetamine-D6 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Amphetamine-D6 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Amphetamine-D8 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Amphetamine-D8 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methamphetamine-D11 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methamphetamine-D11 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methamphetamine-D14 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methamphetamine-D14 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methamphetamine-D8 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methamphetamine-D8 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methamphetamine-D9 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methamphetamine-D9 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited (+)-Norpseudoephedrine Hydrochloride (Cathine Hydrochloride) 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited (R)-(+)-Cathinone Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited (S)-(-)-Cathinone Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited (S)-(-)-Methcathinone Hydrochloride 1.0 mg/mL in Methanol (as free base). Glass vial: 1 mL 11/30/2012
LGC Limited Phentermine 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Fenfluramine Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Methylphenidate-D9 Hydrochloride 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Pipradrol Hydrochloride 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Pipradrol Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited GHB Sodium Salt (Sodium Gammahydroxybutyrate) 1.0 mg/mL in Methanol (as free acid) Glass vial: 1 mL 11/30/2012
LGC Limited GHB–D6 Sodium Salt (Sodium Gammahydroxybutyrate-D6) 0.1 mg/mL in Methanol (as free acid) Glass vial: 1 mL 11/30/2012
LGC Limited GHB–D6 Sodium Salt (Sodium Gammahydroxybutyrate-D6) 1.0 mg/mL in Methanol (as free acid) Glass vial: 1 mL 11/30/2012
LGC Limited Hexobarbital 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Methohexital 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Methohexital-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Phenobarbital 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Phenobarbital-D5 (D-label on ring) 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Phenobarbital-D5 (D-label on ring) 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Phenobarbital-D5 (D-label on side chain) 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Phenobarbital-D5 (D-label on side chain) 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Methaqualone 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Methaqualone-D7 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Clonazepam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Clonazepam-D4 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Chlordiazepoxide 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Chlordiazepoxide-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Bromazepam 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Bromazepam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Clobazam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Delorazepam 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Estazolam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Estazolam-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Flunitrazepam 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Flunitrazepam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Flunitrazepam-D7 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Prazepam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Prazepam-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Diazepam 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Diazepam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Diazepam-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Diazepam-D5 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Flurazepam 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Flurazepam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Lormetazepam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Zaleplon 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Pregabalin 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Pregabalin-D6 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Zolpidem Tartrate 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Zolpidem-D6 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Zopiclone 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Zopiclone Oxide 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Zopiclone-D4 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Meprobamate 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Nitrazepam 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Nitrazepam 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Nitrazepam-D5 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Oxazepam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Oxazepam-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Oxazepam-D5 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Nordazepam (Nordiazepam) 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Nordazepam (Nordiazepam) 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Nordazepam-D5 (Nordiazepam-D5) 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Nordazepam-D5 (Nordiazepam-D5) 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Alprazolam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Alprazolam-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Alprazolam-D5 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Methyltestosterone (17alpha-Methyltestosterone) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Midazolam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Midazolam-D4 Maleate 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Lorazepam 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Lorazepam 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Lorazepam Acetate ((3RS)-7-Chloro-5-(2-chlorophenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepin-3-yl Acetate) 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Lorazepam-D4 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Lorazepam-D4 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Tetrazepam 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Triazolam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Triazolam-D4 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Temazepam 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Temazepam 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Temazepam-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Temazepam-D5 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Androstanolone (5alpha-Dihydrotestosterone, Stanolone) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Androstenedione (Androst-4-ene-3, 17-dione) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Boldenone 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Fluoxymesterone 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Mesterolone 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Methandienone 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Nandrolone 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Norandrostenedione (19-Norandrost-4-ene-3,17-dione) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Norethandrolone 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Stanozolol 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Stanozolol-D3 0.1 mg/mL in 1,2-Dimethoxyethane Glass vial: 1 mL 11/30/2012
LGC Limited Testosterone 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Testosterone Benzoate 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Testosterone Isocaproate 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Testosterone Propionate 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Trenbolone 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited RCS–4 (DD–001, (4-Methoxyphenyl)(1-pentylindol-3-yl)methanone) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited JWH–081 ((4-Methoxynaphthalen-1-yl)(1-pentylindol-3-yl)methanone) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited JWH–122 ((4-Methylnaphthalen-1-yl)(1-pentylindol-3-yl)methanone) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited JWH–203 (2-(2-Chlorophenyl)-1-(1-pentylindol-3-yl)ethanone) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Ketamine Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Ketamine-D4 Hydrochloride 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Iso-LSD (Lysergic Acid Diethylamide) 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited LAMPA (Lysergic Acid N-Methyl-N-propylamide) 0.025 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited LSD (Lysergic Acid Diethylamide) 0.025 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited LSD–D3 (Lysergic Acid Diethylamide-D3) 0.025 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited PMA HCl (p-Methoxyamphetamine) 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited rac-MDA (rac-3,4-Methylenedioxyamphetamine) 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-MDEA (rac-3,4-Methylenedioxy-N-ethylamphetamine) 1.0
mg/mL in Methanol
Glass vial: 1 mL 11/30/2012
LGC Limited 1-Methylamino-1-(3,4-methylenedioxyphenyl)propane Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited rac-BDB HCl (rac-3,4-Methylenedioxyphenyl-2-butanamine Hydrochloride) 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited rac-MDMA (rac-3,4-Methylenedioxymethamphetamine) 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Bufotenine 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Methylone Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Methylone-D3 Hydrochloride 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited AM–694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Cocaine 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Cocaine-D3 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Cocaine-D3 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Norcocaine Hydrochloride 1.0 mg/mL in Acetonitrile (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Norcocaine-D3 Hydrochloride 0.1 mg/mL in Acetonitrile (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited O-Methylcodeine 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Buprenorphine 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Buprenorphine 3-beta-D-Glucuronide 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Buprenorphine-D4 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Dihydrocodeine Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Dihydrocodeine-D6 Hydrochloride 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Noroxycodone Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Noroxycodone-D3 Hydrochloride 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Oxycodone 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Oxycodone-D3 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Dihydromorphine 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Hydromorphone-D3 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Anhydroecgonine Hydrochloride 1.0 mg/mL in Acetonitrile (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Anhydroecgonine Methyl Ester 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Benzoylecgonine 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Benzoylecgonine-D3 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Benzoylecgonine-D3 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Benzoylecgonine-D8 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Benzoylecgonine-D8 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Cocaethylene (Benzoylethylecgonine) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Cocaethylene-D3 (Benzoylethylecgonine-D3) 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Cocaethylene-D8 (Benzoylethylecgonine-D8) 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Ecgonine 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Ecgonine Ethyl Ester 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Ecgonine Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Ecgonine Methyl Ester 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Ecgonine Methyl Ester 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Ecgonine-D3 Hydrochloride 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Ecgonine-D3 Methyl Ester 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Ethylmorphine 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Hydrocodone 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Hydrocodone-D3 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Hydrocodone-D6 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Norhydrocodone Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Heroin (Diacetylmorphine) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Heroin-D9 (Diacetylmorphine-D9) 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Heroin-D9 (Diacetylmorphine-D9) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methadone 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methadone 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methadone-D3 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methadone-D3 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methadone-D9 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited rac-Methadone-D9 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Dextropropoxyphene 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Dextropropoxyphene 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited rac-Propoxyphene-D11 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited rac-Propoxyphene-D11 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited rac-Propoxyphene-D5 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited rac-Propoxyphene-D5 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited 6-Acetylmorphine 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited 6-Acetylmorphine 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited 6-Acetylmorphine-D3 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited 6-Acetylmorphine-D3 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited 6-Acetylmorphine-D6 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited 6-Acetylmorphine-D6 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Acetylcodeine 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Acetylcodeine 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Nordihydromorphine Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Oxymorphone 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Oxymorphone-D3 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Oxymorphone-D3 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Noroxymorphone Hydrochloride 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Noroxymorphone Hydrochloride 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Butorphanol Tartrate 1.0 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited Sufentanil Citrate 0.1 mg/mL in Methanol (as free base) Glass vial: 1 mL 11/30/2012
LGC Limited cis-Tilidine (Ethyl (1R,2RS)-2-(Dimethylamino)-1-phenylcyclohex-3-enecarboxylate) 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited Tilidine 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
Microgenics Corporation Abbott TDM Multiconstituent Calibrator (CAL 1–6) Catalog Number: 5P04–01 Box: 7 vials; 5 mL each 7/2/2012
Microgenics Corporation Thermo Scientific DRI Opiate Assay Catalog Number: 100014602 Vial: 18 mL, Box: 3 vials 1/30/2013
Microgenics Corporation Thermo Scientific DRI Cannabinoid Assay Catalog Number: 10014665 Vial: 18 mL, Box: 3 vials 1/30/2013
Microgenics Corporation Thermo Scientific Phencyclidine Assay Catalog Number: 10014673 Vial: 18 mL, Box: 3 vials 1/30/2013
Microgenics Corporation Thermo Scientific Ecstacy Assay Catalog Number: 10014681 Vial: 18 mL, Box: 3 vials 1/30/2013
Microgenics Corporation Thermo Scientific CEDIA Methamphetamine OFT Calibrator 1: Catalog Number 10016362 Vial: 5 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Methamphetamine OFT Calibrator 2: Catalog Number 10063 Vial: 5 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Methamphetamine OFT Calibrator 3: Catalog Number 10016364 Vial: 5 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Methamphetamine OFT Control 1: Catalog Number 10017686 Vial: 10 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Methamphetamine OFT Control 2: Catalog Number 10017687 Vial: 10 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Methamphetamine OFT Control 3: Catalog Number 1007688 Vial: 10 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Multi-Drug OFT Calibrator 1: Catalog Number 10016882 Vial: 10 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Multi-Drug OFT Calibrator 2: Catalog Number 10016883 Vial: 10 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Multi-Drug OFT Calibrator 3: Catalog Number 10016884 Vial: 10 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Multi-Drug OFT Control 1: Catalog Number 10017711 Vial: 15 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Multi-Drug OFT Control 2: Catalog Number 10017712 Vial: 15 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA Multi-Drug OFT Control 3: Catalog Number 10017713 Vial: 15 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA THC OFT Calibrator 1: Catalog Number 10016700 Vial: 5 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA THC OFT Calibrator 2: Catalog Number 10016701 Vial: 5 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA THC OFT Calibrator 3: Catalog Number 10016702 Vial: 5 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA THC OFT Control 1: Catalog Number 10017702 Vial: 10 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA THC OFT Control 2: Catalog Number 10017703 Vial: 10 mL; Box: 1 vial 2/11/2013
Microgenics Corporation Thermo Scientific CEDIA THC OFT Control 3: Catalog Number 10017704 Vial: 10 mL; Box: 1 vial 2/11/2013
Ortho Clinical Diagnostics, Inc VITROS Immunodiagnostics Products Testosterone Reagent Pack Plastic chamber: 8.4 mL 9/28/2012
Ortho Clinical Diagnostics, Inc VITROS Immunodiagnostics Products Estradiol Reagent Pack Plastic chamber: 13.3 mL 9/28/2012
Ortho Clinical Diagnostics, Inc VITROS Immunodiagnostics Products Testosterone Calibrators (1–3) Box: 3 vials; 2 mL each 10/19/2012
Ortho Clinical Diagnostics, Inc VITROS Immunodiagnostics Products Testosterone Controls (1–3) Box: 9 vials; 1 mL each 10/19/2012
Ortho Clinical Diagnostics, Inc VITROS Immunodiagnostics Products Testosterone Range Verifiers (Low and High) Box: 4 vials; 1–1.5 mL each 10/19/2012
Restek Custom Revised Appendix IX Mix #1 Glass vial: 1.3 mL 2/14/2013
Restek Corporation Product and Reactor Samples Standard Ampule: 2 mL 10/12/2012
Restek Corporation 8270 Supplemental Standard #1 Ampule: 2 mL 12/13/2012
Siemens Healthcare Diagnostics Inc. TTST Stock X (Bulk) Stock container: 50 mL–1 L 7/26/2012
Siemens Healthcare Diagnostics Inc. VS TTST Cal Bulk Soln Level 1 Bulk container: 4 mL–100 L 7/26/2012
Siemens Healthcare Diagnostics Inc. VS TTST Cal Bulk Soln Level 2 Bulk container: 4 mL–100 L 7/26/2012
Siemens Healthcare Diagnostics Inc. VS TTST Cal Bulk Soln Level 3 Bulk container: 4 mL–100 L 7/26/2012
Siemens Healthcare Diagnostics Inc. VS TTST Cal Bulk Soln Level 4 Bulk container: 4 mL–100 L 7/26/2012
Siemens Healthcare Diagnostics Inc. VS TTST Cal Bulk Soln Level 5 Bulk container: 4 mL–100 L 7/26/2012
Siemens Healthcare Diagnostics Inc. VS TTST Cal Bulk Soln Level 6 Bulk container: 4 mL–100 L 7/26/2012
Siemens Healthcare Diagnostics Inc. Dimension Vista TTST CAL A Vial: 1 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. Dimension Vista TTST CAL B Vial: 1 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. Dimension Vista TTST CAL C Vial: 1 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. Dimension Vista TTST CAL D Vial: 1 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. Dimension Vista TTST CAL E Vial: 1 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. Dimension Vista TTST CAL F Vial: 1 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. Dimension Vista System TTST CAL Box: 12 vials; 1 ml each 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST Lvl 1 Bulk Bulk container: 4 mL–20 L 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST Lvl 2 Bulk Bulk container: 4 mL–20 L 7/26/2012
Siemens Healthcare Diagnostics Inc.Siemens Healthcare Diagnostics Inc. MP TTST Lvl 3 Bulk Bulk container: 4 mL–20 L 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST Lvl 4 Bulk Bulk container: 4 mL–20 L 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST Lvl 5 Bulk Bulk container: 4 mL–20 L 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST Lvl 6 Bulk Bulk container: 4 mL–20 L 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST CAL Lvl 1 FC Vial: 1–5 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST CAL Lvl 2 FC Vial: 1–5 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST CAL Lvl 3 FC Vial: 1–5 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST CAL Lvl 4 FC Vial: 1–5 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST CAL Lvl 5 FC Vial: 1–5 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. MP TTST CAL Lvl 6 FC Vial: 1–5 mL 7/26/2012
Siemens Healthcare Diagnostics Inc. TTST Stock S (Bulk) Stock container: 50 mL–1 L 7/26/2012
Siemens Healthcare Diagnostics Inc. TTST Stock T (Bulk) Stock container: 50 mL–1 L 7/26/2012
Siemens Healthcare Diagnostics Inc. Estradiol Diluent Plastic container: 0.5L–1.0L 11/14/2012
Siemens Healthcare Diagnostics Inc. Dimension Vista Drug 1 CAL Pilot, Level B Plastic test tube: 15 mL 12/3/2012
Siemens Healthcare Diagnostics Inc. Titan C18 Batch Test 1 Mix Glass ampule: 1 mL 2/28/2013

The Deputy Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart II below is not consistent with the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23. Accordingly, the Deputy Assistant Administrator has determined that the chemical preparations or mixtures generally described in Chart II below and specifically described in the application materials received by DEA, are not exempt from application of any part of the CSA or from application of any part of the CFR, with regard to the requested exemption pursuant to 21 CFR 1308.23, as of the date listed below that was provided in the determination letters to the individual requesters.

Chart II
Supplier Product name Form Application
date
Agilent Technologies Forensic Toxicology Comprehensive Mix–Submix 9A Ampule: 1 mL 12/6/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC177 Glass vials: 1 ml–200 mL 10/11/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC178 Glass vials: 1 ml–200 mL 10/23/2012
Biochemical Diagnostics, Inc Salivabuse Custom Liquid Control Oral Fluid, OF24 Glass vials: 1 ml–200 mL 10/23/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC180 Glass vials: 1 ml–200 mL 12/14/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC181 Glass vials: 1 ml–200 mL 12/14/2012
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC182 Glass vials: 1 ml–2 L 1/22/2013
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC180 Glass vials: 1 ml–200 mL 1/29/2013
Biochemical Diagnostics, Inc Detectabuse Custom Liquid Control Urine, MC182 Glass vials: 1 ml–2 L 2/14/2013
Cerilliant Corporation (-)-11-nor-9-Carboxy-delta9-THC (1 mg/mL) Glass ampule: 5 mL 7/6/2012
Cerilliant Corporation Cocaine HCl (10 mg/mL) Glass Ampule: 1 mL 7/6/2012
Cerilliant Corporation Lacosamide (10 mg/mL) Glass Ampule: 1 mL 9/12/2012
Cliniqa Corporation TDM Control, Levels 1–3 Bulk Plastic Container: 500 L 12/4/2012
ElSohly Laboratories, Inc ELI Oral Fluid Controls, THC (0.5–50 ng/mL) Glass vial: 5 ml–4 L 8/9/2012
ElSohly Laboratories, Inc ELI Oral Fluid Controls, Methamphetamine (2–200 ng/mL) Glass vial: 5 ml–4 L 8/9/2012
ElSohly Laboratories, Inc ELI  Oral  Fluid  Controls,  Amphetamine,  Benzoylecgonine, Morphine, Phencyclidine (2–200 ng/mL) Glass vial: 5 ml–4 L 8/9/2012
ElSohly Laboratories, Inc ELI Oral Fluid Controls, Multidrug (selected from THC, Cocaine/Benzoylecgonine, Amphetamines, Opiates, & PCP at 0.5–50 ng/mL) Glass vial: 5 ml–4 L 8/9/2012
ElSohly Laboratories, Inc ELI Oral Fluid Calibrators, THC (0.5–50 ng/mL) Glass vial: 5 ml–4 L 8/9/2012
ElSohly Laboratories, Inc ELI Oral Fluid Calibrators, Methamphetamine (2–200 ng/mL) Glass vial: 5 ml–4 L 8/9/2012
ElSohly Laboratories, Inc ELI Oral Fluid Calibrators, Amphetamine, Benzoylecgonine, Morphine, Phencyclidine (2–200 ng/mL) Glass vial: 5 ml–4 L 8/9/2012
ElSohly Laboratories, Inc ELI Oral Fluid Calibrators, Multidrug (selected from THC, Cocaine/Benzoylecgonine, Amphetamines, Opiates, & PCP at 0.5–200 ng/mL) Glass vial: 5 ml–4 L 8/9/2012
LGC Limited LAMPA (Lysergic Acid N-Methyl-N-propylamide) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited LSD (Lysergic Acid Diethylamide) 1.0 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited LSD–D3 (Lysergic Acid Diethylamide-D3) 0.1 mg/mL in Acetonitrile Glass vial: 1 mL 11/30/2012
LGC Limited (-)-Cannabidiol 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Cannabinol 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited (-)-delta9-THC (Dronabinol) 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited (-)-delta9-THC-D3 (Dronabinol-D3) 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited trans-11-Hydroxy-delta9-THC ((6aRS,10aRS)-11-Hydroxy-delta9-tetrahydrocannabinol) 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited trans-11-Hydroxy-delta9-THC  ((6aRS,10aRS)-11-Hydroxy-delta9-tetrahydrocannabinol) 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited trans-11-Hydroxy-delta9-THC-D3 (trans-11-Hydroxy-delta9-tetrahydrocannabinol-D3) 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited trans-11-Nor-9-carboxy-delta9-THC 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited trans-11-Nor-9-carboxy-delta9-THC-D3  0.1  mg/mL  in  Methanol Glass vial: 1 mL 11/30/2012
LGC Limited trans-11-Nor-9-carboxy-delta9-THC-D3  1.0  mg/mL  in  Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Fentanyl 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Fentanyl 1.0 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
LGC Limited Fentanyl-D5 0.1 mg/mL in Methanol Glass vial: 1 mL 11/30/2012
Siemens Healthcare Diagnostics Inc. Dimension Vista Drug 1 CAL Bulk, Level B Plastic container: 4–100 L 12/3/2012

Scope of Approval

The exemptions are applicable only to the precise preparation or mixture described in the application submitted to DEA in the form(s) listed in this order and only for those sections of the CSA and the CFR that are specifically identified. Pursuant to 21 CFR 1308.24(h), any change in the quantitative or qualitative composition of the preparation or mixture or change in the trade name or other designation of the preparation or mixture after the date of application requires a new application. Pursuant to 21 CFR 1308.24(g), DEA may prescribe requirements other than those set forth in 1308.24(b)-(e) on a case-by- case basis for materials exempted in bulk quantities. Accordingly, in order to limit opportunity for diversion from the larger bulk quantities, DEA has determined that each of the exempted bulk products listed in this order may only be used by the manufacturer and may not be distributed by the manufacturer for any purpose or transported to other facilities.

Additional exempt chemical preparation requests received between July 1, 2012, and March 31, 2013, and not otherwise referenced in this order may remain under consideration until DEA receives additional information required, pursuant to 21 CFR 1308.23(d), as detailed in separate correspondence to individual requesters. DEA's order on such requests will be communicated to the public in a future Federal Register publication.

DEA also notes that these exemptions are limited to exemption from only those sections of the CSA and the CFR that are specifically identified in 21 CFR

[[Page 40186]]

1308.24(a). All other requirements of the CSA and the CFR apply, including, but not limited to, registration as an importer as required by 21 U.S.C. 957.

Chemical Preparations Containing Newly Controlled Substances

The statutory authority for exempt chemical preparations is based on the control status of substances contained within a preparation, the intended administration of a preparation, and the packaged form of a preparation. DEA conducts a case-by-case analysis of each application for exemption to determine whether exemption of a preparation from certain provisions of the CSA is appropriate pursuant to the specified statutory and regulatory requirements.

Most exempt chemical preparations have remained effective until the holder of a specific exempt chemical preparation specifically requested that the exemption be terminated. The CSA allows for modifications to the controlled substances schedules to add, remove, or change the schedule of substances thus resulting in periodic modifications to the control status of various substances. 21 U.S.C. 811(a). Since the CSA was enacted in 1970, DEA has on several occasions added to, removed from, or modified the schedules of controlled substances in accordance with the CSA. Such changes may result in the non-compliance of exempt chemical preparations with current statutes or regulations if chemical preparations that have already obtained exempt status contain newly controlled substances. For example, although an exempt chemical preparation may continue to be packaged in the same manner as when it was approved, non-controlled substances in the preparation may become controlled, thus prompting the need for a new application for exemption of the chemical preparation to ensure continued compliance. Other preparations that previously contained no controlled substances may contain newly controlled substances and thus would require an application for exemption.

DEA reviews applications for chemical preparation exemptions based on the statutes and regulations that are in place at the time of the application, including the control status of substances included in the preparation. DEA must remain vigilant to ensure that exempt chemical preparations remain consistent with the standards set forth in the CSA and its implementing regulations. As such, DEA reminds the public that any chemical preparation, regardless of whether it was previously exempt, that contains a newly controlled substance will require a new application for exemption pursuant to 21 U.S.C. 811(g)(3)(B) and 21 CFR 1308.23-1308.24.

Review of Exemptions Pursuant to 21 U.S.C. 811(g)(3)

Based on inquiries received from industry, DEA is conducting a comprehensive review of the exempt chemical preparation regulations. DEA's regulations at 21 CFR 1308.24(a) state that approved chemical preparations are exempt from certain provisions of both Subchapter I and Subchapter II of the CSA: "The chemical preparations and mixtures approved pursuant to 1308.23 are exempt from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003 and 1004 of the Act (21 U.S.C. 822-823, 825-829, 952-954) and 1301.74 of this chapter, to the extent described in paragraphs (b) to (h) of this section." Pursuant to its regulations, DEA has provided exemptions from the application of section 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 of the Act (21 U.S.C. 822-823, 825-829, 952-954) and 21 CFR 1301.74 since the implementation of the regulations in the early 1970s. Until DEA's analysis of the exemption regulations is complete, DEA will continue to review and provide exemptions to chemical preparations consistent with the implementing regulations, when warranted. DEA will publish a future notice regarding the outcome of DEA's review of its regulations with respect to the exemption of chemical preparations.

Opportunity for Comment

Pursuant to 21 CFR 1308.23, any interested person may submit written comments on or objections to any chemical preparation in this order that has been approved or denied as exempt. If any comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which this order is based, the Deputy Assistant Administrator will immediately suspend the effectiveness of any applicable part of this order until he may reconsider the application in light of the comments and objections filed.

Approved Exempt Chemical Preparations Are Posted on DEA's Web Site

A list of all current exemptions, including those listed in this order, is available on DEA's Web site at http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt_chemlist.pdf. The dates of applications of all current exemptions are posted for easy reference.

Dated: June 17, 2013.

Joseph T. Rannazzisi,
Deputy Assistant Administrator.

[FR Doc. 2013-16010 Filed 7-2-13; 8:45 am]

BILLING CODE 4410-09-P

 

NOTICE: This is an unofficial version. An official version of this publication may be obtained directly from the Government Printing Office (GPO).

Emergency Disaster Relief
National Prescription Drug Take Back Day. Turn in your unused or expired medication for safe disposal here.
RX Abuse Online

U.S. DEPARTMENT OF JUSTICE  •  DRUG ENFORCEMENT ADMINISTRATION
Diversion Control Division  •  8701 Morrissette Drive  •  Springfield, VA 22152  •  1-800-882-9539

DOJ Legal Policies and Disclaimers    |    DOJ Privacy Policy    |    FOIA    |    Section 508 Accessibility